Odonate Therapeutics Inc (NASDAQ:ODT) CEO Kevin C. Tang bought 76,308 shares of Odonate Therapeutics stock in a transaction dated Friday, June 7th. The shares were acquired at an average price of $27.36 per share, with a total value of $2,087,786.88. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of Odonate Therapeutics stock traded down $1.27 on Monday, hitting $24.88. 62,800 shares of the company’s stock traded hands, compared to its average volume of 58,122. The stock has a market cap of $699.43 million, a P/E ratio of -6.84 and a beta of 0.60. Odonate Therapeutics Inc has a 52-week low of $11.54 and a 52-week high of $28.57.
Odonate Therapeutics (NASDAQ:ODT) last released its earnings results on Thursday, April 25th. The company reported ($1.16) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.24) by $0.08. Equities analysts forecast that Odonate Therapeutics Inc will post -4.43 EPS for the current year.
Several equities analysts have recently commented on the company. Zacks Investment Research upgraded Odonate Therapeutics from a “sell” rating to a “hold” rating and set a $22.00 target price for the company in a research note on Tuesday, April 30th. ValuEngine upgraded Odonate Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Finally, Cowen reiterated a “buy” rating on shares of Odonate Therapeutics in a research note on Friday, February 22nd.
WARNING: “Insider Buying: Odonate Therapeutics Inc (NASDAQ:ODT) CEO Purchases 76,308 Shares of Stock” was reported by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://dakotafinancialnews.com/2019/06/11/insider-buying-odonate-therapeutics-inc-nasdaqodt-ceo-purchases-76308-shares-of-stock.html.
About Odonate Therapeutics
Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.
Featured Story: What is Cost of Goods Sold (COGS)?
Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.